In this Issue:
Human HSCs are refractory to HCV infection
Causes of death after chronic HBV infection
Horizontally acquired HBV in NZ Māori: long-term data
TLR7 agonist shows promise for chronic HBV infection
All-oral antiviral regimen in post-LT HCV GT1 infection
Cost-effectiveness of immediate HCV therapy in early disease
New models for predicting risk of HCV progression
HBV genotype and integration patterns in HCC
Antiviral therapy beneficial in HBV-related decompensated cirrhosis
Ledipasvir-sofosbuvir + ribavirin in previously treated HCV
Please login below to download this issue (PDF)